Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00286832 |
Recruitment Status
:
Completed
First Posted
: February 6, 2006
Last Update Posted
: July 6, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Diffuse Large-Cell Lymphoma | Procedure: PET scan |
Title: Evaluation of response to treatment using 18F-FDG positron emission tomography imaging (PET) in diffuse large B-cell lymphoma stage IIB-IV with special emphasize on the prognostic significance of early on-therapy PET at first-line treatment
Study design: Multicenter trial.
Planned sample size: 100 patients.
Number of centers: Denmark 2; Sweden 1; Norway 1; Finland 1.
Aim of the study: 1. To evaluate the prognostic significance of PET early after treatment initiation. 2. To compare early PET with standard response criteria for NHL and the International Prognostic Index (IPI) in the prediction of response and outcome.
Primary objective: The prognostic significance of FDG-PET after 1 cycle of chemotherapy.
End-points: Progression-free survival (PFS). Overall survival (OS). Response to treatment (standardized response criteria) at mid-treatment and post-treatment.
Inclusion criteria:
Age ≥ 18 years. Newly diagnosed consecutive patients with diffuse large B-cell lymphoma (DLBCL) according to the WHO classification.
Ann Arbor stage IIB-IV. Written informed consent.
Exclusion criteria: Previously treated with chemotherapy or irradiation. Previous malignant diagnosis except basal cell carcinoma and cervical carcinoma in situ.
Pregnancy. Lactation. Diabetes mellitus. Extreme adipositas. Claustrophobia. Active inflammatory disease or infection.
PET-CT evaluation: PET and CT at primary staging before initiation of therapy and PET after one cycle of intravenous chemotherapy (day 10-20) are mandatory. The results of the PET scans are blinded and will not be available for the local physicians. If the PET result is opened, the patient will be excluded from the study.
Only post-treatment PET scans are allowed outside the protocol. The local physician may use post-treatment PET in diagnostic or therapeutic considerations.
Only dedicated full-ring PET scanners are allowed in this study.
Treatment: Therapy with a CHOP-like backbone according to local standards of the individual centers. Treatment according to other protocols allowed.
Study Type : | Observational |
Actual Enrollment : | 100 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Evaluation of Response to Treatment Using 18F-FDG Positron Emission Tomography Imaging (PET) With Special Emphasize on the Prognostic Significance of Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV |
Study Start Date : | August 2005 |
Actual Primary Completion Date : | January 2011 |
Actual Study Completion Date : | January 2011 |

Group/Cohort | Intervention/treatment |
---|---|
Single group study |
Procedure: PET scan
One extra PET scan after 1 cycle of treatment.
Other Name: positron emission tomography
|

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age ≥ 18 years.
- Newly diagnosed consecutive patients with diffuse large B-cell lymphoma (DLBCL) according to the WHO classification.
- Ann Arbor stage IIB-IV.
- Written informed consent.
Exclusion Criteria:
- Previously treated with chemotherapy or irradiation.
- Previous malignant diagnosis except basal cell carcinoma and cervical carcinoma in situ.
- Pregnancy.
- Lactation.
- Diabetes mellitus.
- Extreme adipositas.
- Claustrophobia.
- Active inflammatory disease or infection.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00286832
Denmark | |
Department of Hematology, Odense University Hospital | |
Odense, Denmark, 5000 |
Principal Investigator: | Lars M Pedersen, MD | Nordic Lymphoma Group (Large Cell Group) |
Responsible Party: | Lars M Pedersen, MD, Nordic Lymphoma Group (NLG) |
ClinicalTrials.gov Identifier: | NCT00286832 History of Changes |
Other Study ID Numbers: |
NLG PET Study |
First Posted: | February 6, 2006 Key Record Dates |
Last Update Posted: | July 6, 2011 |
Last Verified: | July 2011 |
Keywords provided by Copenhagen University Hospital at Herlev:
Non-Hodgkin's lymphoma Diffuse large B-cell lymphoma PET Prognosis |
Additional relevant MeSH terms:
Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin |